Capecitabine

From Wikipedia, the free encyclopedia - View original article

Capecitabine
Capecitabine2DACS2.svg
Capecitabine3Dan.gif
Systematic (IUPAC) name
Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]carbamate
Clinical data
Trade namesXeloda
AHFS/Drugs.commonograph
MedlinePlusa699003
Pregnancy cat.D (AU) D (US)
Legal statusPrescription Only (S4) (AU) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
BioavailabilityExtensive
Protein binding< 60%
MetabolismHepatic, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil
Half-life38–45 minutes
ExcretionRenal (95.5%), faecal (2.6%)
Identifiers
CAS number154361-50-9 YesY
ATC codeL01BC06
PubChemCID 60953
DrugBankDB01101
ChemSpider54916 YesY
UNII6804DJ8Z9U YesY
KEGGD01223 YesY
ChEBICHEBI:31348 YesY
ChEMBLCHEMBL1773 YesY
Chemical data
FormulaC15H22FN3O6 
Mol. mass359.35 g/mol
 YesY (what is this?)  (verify)
 
  (Redirected from Xeloda)
Jump to: navigation, search
Capecitabine
Capecitabine2DACS2.svg
Capecitabine3Dan.gif
Systematic (IUPAC) name
Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]carbamate
Clinical data
Trade namesXeloda
AHFS/Drugs.commonograph
MedlinePlusa699003
Pregnancy cat.D (AU) D (US)
Legal statusPrescription Only (S4) (AU) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
BioavailabilityExtensive
Protein binding< 60%
MetabolismHepatic, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil
Half-life38–45 minutes
ExcretionRenal (95.5%), faecal (2.6%)
Identifiers
CAS number154361-50-9 YesY
ATC codeL01BC06
PubChemCID 60953
DrugBankDB01101
ChemSpider54916 YesY
UNII6804DJ8Z9U YesY
KEGGD01223 YesY
ChEBICHEBI:31348 YesY
ChEMBLCHEMBL1773 YesY
Chemical data
FormulaC15H22FN3O6 
Mol. mass359.35 g/mol
 YesY (what is this?)  (verify)

Capecitabine (INN) /kpˈstəbn/ (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers.[1] Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil (5-FU) in the body.[2]

Medical uses[edit]

It is used in the treatment of the following cancers:[1][2][3]

Adverse effects[edit]

Adverse effects by frequency:[4][5][6][7]

Very common (>10% frequency)
Common (1-10% frequency)
Uncommon (0.1-1% frequency)
Rare (<0.1% frequency)
  • Lacrimal duct stenosis
  • Ventricular fibrillation
  • QT prolongation
  • Torsade de pointes
  • Bradycardia
  • Vasospasm
  • Liver failure
  • Cholestatic hepatitis

Notes on adverse effects:

  1. ^ Includes: anaemia, lymphopenia, neutropenia and thrombocytopenia
  2. ^ Includes pneumonia
  3. ^ Angina-like chest pain appears to be the most common symptom. Less common cardiac symptoms include (all of these side effects are uncommon, i.e. they occur in less than 1% of patients):
    • Tachycardia
    • Arrhythmias
    • Heart failure
    • Myocardial infarction (heart attack)
    • Cardiac arrest
    Usually occurs during the first 2-3 days of treatment is thought to be due to coronary vasospasm. Appears to resolve after capecitabine is stopped and to recur if it is restarted

Contraindications[edit]

Contraindications include:[6]

Drug interactions[edit]

Drugs it is known to interact with includes:[6]

Mechanism of action[edit]

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

[[File:
FluoropyrimidineActivity_WP1601go to articlego to articlego to articlego to pathway articlego to pathway articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to PubChem Compoundgo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to pathway articlego to pathway articlego to articlego to articlego to articlego to articlego to articlego to WikiPathwaysgo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
FluoropyrimidineActivity_WP1601go to articlego to articlego to articlego to pathway articlego to pathway articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to PubChem Compoundgo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to pathway articlego to pathway articlego to articlego to articlego to articlego to articlego to articlego to WikiPathwaysgo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
|{{{bSize}}}px|class=noresize]]
Fluorouracil (5-FU) Activity edit
  1. ^ The interactive pathway map can be edited at WikiPathways: "FluoropyrimidineActivity_WP1601". 

Capecitabine is metabolised to 5-FU which in turn is a thymidylate synthase inhibitor, hence inhibiting the synthesis of thymidine monophosphate (ThMP), the active form of thymidine which is required for the de novo synthesis of DNA and RNA during gene expression.[2]

References[edit]

  1. ^ a b c Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.  edit
  2. ^ a b c "Xeloda (capecitabine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. 25 January 2014. 
  3. ^ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.  edit
  4. ^ "XELODA (capecitabine) tablet, film coated [Genentech, Inc.]". DailyMed. Genentech, Inc. December 2013. Retrieved 25 January 2014. 
  5. ^ "Capecitabine Teva : EPAR - Product Information" (PDF). European Medicines Agency. Teva Pharma B.V. 10 January 2014. Retrieved 25 January 2014. 
  6. ^ a b c "Capecitabine 150mg - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Zentiva. 23 December 2013. Retrieved 25 January 2014. 
  7. ^ "NAME OF THE MEDICINE XELODA® Capecitabine" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 5 December 2013. Retrieved 25 January 2014. 
  8. ^ Reddening, swelling, numbness and desquamation on palms and soles

External links[edit]